Total Funding
62
43
Total FundingSeries B raised
Growth Score
-2 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
82701
NeRRe Therapeutics is a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists.
- Mary Kerr: CEOPast Role: GlaxoSmithKline, SVP and Global Franchise Head
- Mike Trower: Founder, Chief Scientific Officer & Chief Operating OfficerPast Role: GlaxoSmithKline, VP & Head Functional Genomics, Genetics Research
About the Company
NeRRe Therapeutics Ltd. operates as a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists. The company was founded in 2012 and is based in Stevenage, United Kingdom.
